EUCTR2014-003811-13-NL
Active, not recruiting
Phase 1
Selecting cancer patients for treatment using Tumor Organoids, the SENSOR study - SENSOR
Antoni van Leeuwenhoek - Netherlands Cancer Institute0 sites70 target enrollmentMarch 23, 2016
ConditionsColorectal cancer and non-small cell lung cancerTherapeutic area: Diseases [C] - Cancer [C04]
DrugsInlyta
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Colorectal cancer and non-small cell lung cancer
- Sponsor
- Antoni van Leeuwenhoek - Netherlands Cancer Institute
- Enrollment
- 70
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Patients with locally advanced (incurable) or metastatic colorectal cancer or NSCLC that have only one line standard of care treatment left, or will start with a study treatment. Patients should have received a first line standard of care treatment.
- •2\.Patients for whom treatment with curative intent is not an option
- •3\.RECIST 1\.1 evaluable metastatic or locally advanced lesion(s).
- •4\.Metastatic or locally advanced lesion(s) of which a histological biopsy can safely be obtained
- •5\.Adequate kidney and liver function.
- •6\. WHO performance status 0\-1
- •7\. Informed consent
- •8\. 18 years or older
- •Additional in\- and exclusion criteria are provided for each experimental compound
- •Are the trial subjects under 18? no
Exclusion Criteria
- •1\.Pregnant or lactating (nursing) women
- •2\.Prior malignancy within 5 years. Patients with a history of non\-melanomatous skin cancer, successfully treated carcinoma in situ or with a disease free period of \> 5 years may be included.
- •3\.Known infection with human immunodeficiency virus (HIV).
- •4\.Leptomeningeal carcinomatosis.
- •5\.Symptomatic brain metastasis. Patients that are asymptomatic and have been stable for 3 months (confirmed by MRI/CT scan) are eligible for participation if they are not receiving corticosteroid therapy or anti\-epileptic drugs.
- •6\.Other psychiatric or medical conditions that would make the patient unfit for participation due to an increase in the risk associated with study participation or incompliance with study procedures.
- •7\.Life expectancy of less than 3 months from tumor progression under standard of care.
- •Additional in\- and exclusion criteria are provided for each experimental compound
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
utritional therapy for cancer patientHealth Condition 1: C509- Malignant neoplasm of breast of unspecified siteCTRI/2021/03/031634Rajiv Gandhi university of Health Sciences Grant in aid for advanced research project100
Not yet recruiting
Not Applicable
PRospective tumor sampling in oncology patients with solid tumors treated with Immune Modulating AgentsNL-OMON54892Erasmus MC, Universitair Medisch Centrum Rotterdam350
Completed
Phase 2
Towards patient tailored cancer treatment supported by molecular imaging IMPACT: IMaging PAtients for Cancer drug selecTion - Metastatic Breast Cancermammacarcinomametastatic breast cancer10006291NL-OMON41527niversitair Medisch Centrum Groningen200
Active, not recruiting
Not Applicable
Imaging patients for cancer drug selection - metastatic breast cancerMetastatic Breast CancerTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-000551-41-NLniversity Medical Center Groningen
Completed
Not Applicable
Protocol to obtain tumor biopsies from patients with locally advanced (incurable) or metastatic cancer to improve selection for clinical trials.metastatic cancermetastatic malignancy10027476NL-OMON40487niversitair Medisch Centrum Utrecht1,500